
Idiopathic Pulmonary Fibrosis - Pipeline Insight, 2025
Description
DelveInsight’s, “Idiopathic Pulmonary Fibrosis - Pipeline Insight, 2025” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Idiopathic Pulmonary Fibrosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Idiopathic Pulmonary Fibrosis: Overview
Idiopathic pulmonary fibrosis (IPF) is a lung disorder where there is scarring of the lungs from an unknown cause. It is usually a progressive disease with a poor long-term prognosis. The classic features of the disorder include progressive dyspnea and a nonproductive cough. Pulmonary function tests usually reveal restrictive impairment and diminished carbon monoxide diffusing capacity.
Environmental factors like smoking, chronic aspiration, or viral infections, along with advancing age, can lead to respiratory alveolar epithelial injury and are thought to be the likely driving factors for the pathogenesis of IPF. With an epithelial injury, there is an activation of fibroblasts and dysregulated repair of the alveolar epithelium. When this leads to increased matrix deposition in the lung interstitium and scarring, there is a destruction of lung architecture that results in pulmonary fibrosis.[7] The destruction of lung architecture impairs gas exchange and will progress to hypoxic respiratory failure, a hallmark of advanced disease.
The most common presenting symptoms of IPF are dyspnea on exertion and cough, followed by fatigue. The diagnosis is often delayed, as most patients are diagnosed more than a year after symptom onset. Since symptoms are nonspecific and the disease is idiopathic, other conditions must be excluded before diagnosis. History of exposure to inhaled dust, metals, asbestos, mold, or birds should be elicited to exclude other interstitial lung diseases. The diagnosis can be made without biopsy if there are compatible imaging tests, appropriate clinical history, and exclusion of other conditions. The classic pattern of imaging on computed tomography (CT) scan will show a peripheral distribution of bilateral fibrosis, more pronounced at the bases. If there is diagnostic uncertainty, IPF can also be diagnosed by lung biopsy.
Pulmonary function tests every 3 to 6 months should be performed based on symptoms and the disease's progression. However, serial chest imaging is not always necessary. Tools like GAP (gender, age physiology) score issue points for the male gender, advanced age, forced vital capacity, and diffusing capacity or transfer factor of the lung for carbon monoxide and can be used to assess long-term prognosis, with a high GAP score indicating worse mortality. This is mainly used when considering a patient for a lung transplant referral. It is also important to assess the patient's functional status objectively and screen for hypoxic respiratory failure. Most Interstitial Lung Disease specialty centers use the 6-minute walk test to accomplish both. The treatment includes supportive measures, oxygen supplementation when needed, anti-fibrotic drugs, and lung transplants for severe disease.
""Idiopathic Pulmonary Fibrosis- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Idiopathic Pulmonary Fibrosis pipeline landscape is provided which includes the disease overview and Idiopathic Pulmonary Fibrosis treatment guidelines. The assessment part of the report embraces, in depth Idiopathic Pulmonary Fibrosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Idiopathic Pulmonary Fibrosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Idiopathic Pulmonary Fibrosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Idiopathic Pulmonary Fibrosis Emerging Drugs
Further product details are provided in the report……..
Idiopathic Pulmonary Fibrosis: Therapeutic Assessment
This segment of the report provides insights about the different Idiopathic Pulmonary Fibrosis drugs segregated based on following parameters that define the scope of the report, such as:
Idiopathic Pulmonary Fibrosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Idiopathic Pulmonary Fibrosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Idiopathic Pulmonary Fibrosis drugs.
Idiopathic Pulmonary Fibrosis Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Idiopathic Pulmonary Fibrosis: Overview
Idiopathic pulmonary fibrosis (IPF) is a lung disorder where there is scarring of the lungs from an unknown cause. It is usually a progressive disease with a poor long-term prognosis. The classic features of the disorder include progressive dyspnea and a nonproductive cough. Pulmonary function tests usually reveal restrictive impairment and diminished carbon monoxide diffusing capacity.
Environmental factors like smoking, chronic aspiration, or viral infections, along with advancing age, can lead to respiratory alveolar epithelial injury and are thought to be the likely driving factors for the pathogenesis of IPF. With an epithelial injury, there is an activation of fibroblasts and dysregulated repair of the alveolar epithelium. When this leads to increased matrix deposition in the lung interstitium and scarring, there is a destruction of lung architecture that results in pulmonary fibrosis.[7] The destruction of lung architecture impairs gas exchange and will progress to hypoxic respiratory failure, a hallmark of advanced disease.
The most common presenting symptoms of IPF are dyspnea on exertion and cough, followed by fatigue. The diagnosis is often delayed, as most patients are diagnosed more than a year after symptom onset. Since symptoms are nonspecific and the disease is idiopathic, other conditions must be excluded before diagnosis. History of exposure to inhaled dust, metals, asbestos, mold, or birds should be elicited to exclude other interstitial lung diseases. The diagnosis can be made without biopsy if there are compatible imaging tests, appropriate clinical history, and exclusion of other conditions. The classic pattern of imaging on computed tomography (CT) scan will show a peripheral distribution of bilateral fibrosis, more pronounced at the bases. If there is diagnostic uncertainty, IPF can also be diagnosed by lung biopsy.
Pulmonary function tests every 3 to 6 months should be performed based on symptoms and the disease's progression. However, serial chest imaging is not always necessary. Tools like GAP (gender, age physiology) score issue points for the male gender, advanced age, forced vital capacity, and diffusing capacity or transfer factor of the lung for carbon monoxide and can be used to assess long-term prognosis, with a high GAP score indicating worse mortality. This is mainly used when considering a patient for a lung transplant referral. It is also important to assess the patient's functional status objectively and screen for hypoxic respiratory failure. Most Interstitial Lung Disease specialty centers use the 6-minute walk test to accomplish both. The treatment includes supportive measures, oxygen supplementation when needed, anti-fibrotic drugs, and lung transplants for severe disease.
""Idiopathic Pulmonary Fibrosis- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Idiopathic Pulmonary Fibrosis pipeline landscape is provided which includes the disease overview and Idiopathic Pulmonary Fibrosis treatment guidelines. The assessment part of the report embraces, in depth Idiopathic Pulmonary Fibrosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Idiopathic Pulmonary Fibrosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Idiopathic Pulmonary Fibrosis R&D. The therapies under development are focused on novel approaches to treat/improve Idiopathic Pulmonary Fibrosis.
This segment of the Idiopathic Pulmonary Fibrosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Idiopathic Pulmonary Fibrosis Emerging Drugs
- Pamrevlumab: FibroGen
- Tipelukast: MediciNova
- PLN-74809: Pliant Therapeutics
- HZN-825: Horizon Pharmaceuticals
- Brilaroxazine: Reviva Pharmaceuticals
Further product details are provided in the report……..
Idiopathic Pulmonary Fibrosis: Therapeutic Assessment
This segment of the report provides insights about the different Idiopathic Pulmonary Fibrosis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Idiopathic Pulmonary Fibrosis
- There are approx. 80+ key companies which are developing the therapies for Idiopathic Pulmonary Fibrosis. The companies which have their Idiopathic Pulmonary Fibrosis drug candidates in the most advanced stage, i.e. phase III include, FibroGen.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Idiopathic Pulmonary Fibrosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Idiopathic Pulmonary Fibrosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Idiopathic Pulmonary Fibrosis drugs.
Idiopathic Pulmonary Fibrosis Report Insights
- Idiopathic Pulmonary Fibrosis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Idiopathic Pulmonary Fibrosis drugs?
- How many Idiopathic Pulmonary Fibrosis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Idiopathic Pulmonary Fibrosis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Idiopathic Pulmonary Fibrosis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Idiopathic Pulmonary Fibrosis and their status?
- What are the key designations that have been granted to the emerging drugs?
- FibroGen
- United Therapeutics
- Bellerophon Therapeutics
- MediciNova
- Novartis
- Endeavor BioMedicines
- Pliant Therapeutics
- Nitto Denko
- Kadmon Pharmaceuticals
- Calliditas Therapeutics
- Avalyn Pharmaceuticals
- PureTech Health
- Taiho Pharmaceutical
- Bristol-Myers Squibb
- Galecto Biotech AB
- CSL Behring
- Celgene Pharmaceutical
- Vicore Pharma
- Boehringer Ingelheim
- Guangdong Raynovent
- Sunshine Lake Pharma co
- Suzhou Zelgen Biopharmaceuticals
- Algernon Pharmaceuticals
- Horizon Therapeutics
- Daewoong Pharmaceutical
- Metagone Biotech
- AstraZeneca
- Lung Therapeutics
- Bridge Biotherapeutics
- AstraZeneca
- Kinarus AG
- Insmed
- Reviva Pharmaceuticals
- Annapurna Bio
- Guangdong Hengrui Pharmaceutical Co., Ltd.
- Ark Biosciences
- Ocean Biomedical
- Pamrevlumab
- Treprostinil
- Nitric oxide inhalation – INOpulse
- MN-001 (tipelukast)
- VAY736
- ENV-101
- PLN-74809
- ND-L02-s0201
- KD025
- GKT137831
- AP 01
- LYT-100
- TAS-115
- BMS-986278
- GB0139
- CSL312
- CC-90001
- C21
- BI1015550
- ZSP1603
- HEC585
- Jaktinib Dihydrochloride Monohydrate
- Ifenprodil
- HZN-825
- DWN12088
- MG-S-2525
- Saracatinib
- LTI-03
- BBT-877
- AZD5055
- KIN001-IPF
- Treprostinil palmitil inhalation powder (TPIP)
- Brilaroxazine
- ANPA 0073
- SHR 1906
- AK 3280
- OCF 203
Table of Contents
250 Pages
- Introduction
- Executive Summary
- Idiopathic Pulmonary Fibrosis: Overview
- Introduction
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Treatment
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Idiopathic Pulmonary Fibrosis– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Pamrevlumab: FibroGen
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Tipelukast: MediciNova
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- Brilaroxazine: Reviva Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Idiopathic Pulmonary Fibrosis Key Companies
- Idiopathic Pulmonary Fibrosis Key Products
- Idiopathic Pulmonary Fibrosis- Unmet Needs
- Idiopathic Pulmonary Fibrosis- Market Drivers and Barriers
- Idiopathic Pulmonary Fibrosis- Future Perspectives and Conclusion
- Idiopathic Pulmonary Fibrosis Analyst Views
- Idiopathic Pulmonary Fibrosis Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.